Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence

11 Mar 2020

Abstract excerpt

BACKGROUND: Emerging data suggest that a subset of patients with diffuse isocitrate dehydrogenase (IDH)-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors. It is currently unclear why some TMZ-treated LGG patients recur with hypermutation while others do not. MGMT encodes O6-methylguanine-DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32166314
DOI: 10.1093/neuonc/noaa059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrencePMID 32166314Read ↗

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Semantic proximity Read ↗

Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.Semantic proximity Read ↗

A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.Semantic proximity Read ↗

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentSemantic proximity Read ↗

Temozolomide-associated hypermutation in gliomas.Semantic proximity Read ↗

Epigenetic evolution of isocitrate dehydrogenase-wildtype glioblastomas.Semantic proximity Read ↗

Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.Semantic proximity Read ↗

Distinct epigenetic shift in a subset of Glioma CpG island methylator phenotype (G-CIMP) during tumor recurrenceSemantic proximity Read ↗

Glioblastoma recurrence and the role of MGMT promoter methylationSemantic proximity Read ↗

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent GliomaSemantic proximity Read ↗

Variations in DNA Repair Genes and Intratumoral Genetic Heterogeneity in Temozolomide-Resistant Glioblastoma.Semantic proximity Read ↗

Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.